Neuraxis (NRXS) Total Non-Current Liabilities (2022 - 2026)
Neuraxis (NRXS) posted Total Non-Current Liabilities of -$48306.0 for Q1 2026, down 122.73% sequentially from $212565.0 in Q4 2025, and down 107.21% YoY from $670127.0 in Q1 2025.
Neuraxis (NRXS) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Neuraxis has reported Total Non-Current Liabilities for 5 years, with the latest figure at -$48306.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 107.21% year-over-year to -$48306.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$48306.0 (down 107.21% YoY) and the FY2025 annual result came in at $212565.0, down 17.13% from the prior year.
- Total Non-Current Liabilities declined to -$48306.0 in Q1 2026 per NRXS's latest filing, from $212565.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $670127.0 in Q1 2025 and troughed at -$1.9 million in Q1 2023.
- A 5-year average of $78097.1 and a median of $234532.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities surged 847.5% in 2024, then sank 107.21% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $76199.0 in 2022, then slumped by 64.47% to $27071.0 in 2023, then soared by 847.5% to $256499.0 in 2024, then decreased by 17.13% to $212565.0 in 2025, then tumbled by 122.73% to -$48306.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered -$48306.0, $212565.0, and $344239.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | -45,857.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45,857.00 |
| Mar 31, 2026 | -48,306.00 |
| Dec 31, 2025 | 212,565.00 |
| Sep 30, 2025 | 344,239.00 |
| Jun 30, 2025 | 487,420.00 |
| Mar 31, 2025 | 670,127.00 |
| Dec 31, 2024 | 256,499.00 |
| Sep 30, 2024 | 273,075.00 |
| Jun 30, 2024 | 297,843.00 |
| Mar 31, 2024 | 314,472.00 |
| Dec 31, 2023 | 27,071.00 |
| Sep 30, 2023 | 39,353.00 |
| Jun 30, 2023 | 90,432.00 |
| Mar 31, 2023 | -1.95 Mn |
| Dec 31, 2022 | 76,199.00 |